Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
Biogen Inc. (BIIB) reported that Head of Research Jane Grogan exercised or converted 695 restricted stock units and acquired 695 common shares on October 30, 2026. She also reported 345 common shares delivered or withheld for payment of exercise price or tax liability, at a reported price of $253.62 per share. The units vest in three equal yearly installments beginning on the first anniversary of the November 1, 2023 grant date.
Biogen Inc. (BIIB) reported third-quarter 2026 revenue of $2.8041 billion, compared with $2.5347 billion a year earlier, but recorded a $20.6 million net loss attributable to Biogen after $466.5 million of net income in the prior-year quarter. Total costs and expenses were $2.8131 billion, versus $1.9774 billion. For the first nine months, net income was $396.4 million, compared with $1.3418 billion.
Biogen completed its Apellis acquisition on May 14, with total consideration transferred of $5.4101 billion. Apellis shareholders were entitled to $41.00 in cash per share and one contingent value right per share for up to $4.00 in cash, subject to specified annual global net sales thresholds for SYFOVRE. Third-quarter SYFOVRE and EMPAVELI product revenue totaled $242.8 million.
Biogen completed its RayThera acquisition on August 6, paying $225.0 million upfront, recorded as acquired in-process research and development expense; additional development and regulatory milestones may reach up to $275.0 million and $500.0 million, respectively. Third-quarter restructuring charges were $66.5 million, compared with $7.4 million a year earlier, primarily for employee severance and accelerated bonus payments for Apellis employees subject to a double-trigger provision.
Biogen Inc. (BIIB) reported third-quarter 2026 revenue of $2.8041 billion, up 11% year over year. Growth Portfolio revenue was $1.26 billion, up 49%, and represented 63% of Core Pharmaceutical revenue. Rare disease revenue rose 27% to $676 million, while multiple sclerosis product revenue declined 13% to $919 million. GAAP diluted EPS was a loss of $0.14, compared with $3.17 earnings a year earlier; non-GAAP diluted EPS was $2.62, down 46% from $4.81. The quarter included $284 million of acquired IPR&D, upfront and milestone expense, primarily related to the RayThera Inc. acquisition.
For full-year 2026, Biogen raised the lower end of its non-GAAP diluted EPS guidance to $12.20 from $12.00, with the upper end at $13.00. It expects total revenue to increase by a mid-single digit percentage and combined non-GAAP R&D and SG&A expense to be approximately $4.95 billion. Guidance assumes foreign-exchange rates as of October 23, 2026 remain in effect for the rest of the year, net of hedging activities.
Biogen Chief Accounting Officer Sean Godbout reported converting 27 restricted stock units into 27 common shares on October 2, 2026. On the same date, 8 shares were delivered or withheld for payment of exercise price or tax liability. He also acquired 985 restricted stock units on October 1, 2026; those units vest in three equal yearly installments beginning on the first anniversary of the grant. The converted units were scheduled to vest in three equal yearly installments beginning on the first anniversary of their October 2, 2023 grant.
BIOGEN INC. (symbol: BIIB) is the issuer of record for a Form 4 filing submitted to the SEC. Parini Michael reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. (BIIB) reported that Chief Legal Officer Michael Parini received a grant of 7,405 Restricted Stock Units on September 1, 2026. The RSUs represent an equivalent number of shares of common stock and were awarded at a stated price of $0.00 per unit as an equity compensation award.
The RSUs vest in three equal yearly installments, beginning on the first anniversary of the grant date, September 1, 2026, and carry an expiration date of September 1, 2029. Following this grant, Parini holds 7,405 RSUs directly. No Rule 10b5-1 trading plan is reported for this award.
BIOGEN INC. filed an initial statement of beneficial ownership for executive Michael Parini, who serves as Chief Legal Officer. The filing reports no equity transactions or specific share holdings and notes that a Power of Attorney authorizing filings is attached as an exhibit.
FMR LLC and Abigail P. Johnson report beneficial ownership of 18,294,523.51 shares of Biogen Inc. common stock, representing 12.4% of the class. FMR LLC has sole voting power over 16,623,432.57 shares and sole dispositive power over all 18,294,523.51 shares.
Abigail P. Johnson reports sole dispositive power over the same 18,294,523.51 shares, with no voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no single such person holds more than five percent of Biogen’s outstanding common stock.
Biogen Inc. director Lloyd Minor reported selling a total of 1,186 shares of Biogen common stock in two open-market or private transactions. On 3 August 2026 he sold 593 shares at $203.34 per share, and on 4 August 2026 he sold 593 shares at $200.96 per share.
The trades involve non-derivative common stock held directly and are affirmed as having been executed under a Rule 10b5-1 trading plan.
Lloyd Minor reported a planned or recent sale of company common stock. The notice covers 593 shares of common stock held at Fidelity Brokerage Services, originally acquired through restricted stock vesting on 06/09/2026 as compensation from the issuer. The filing also lists a sale of 593 common shares on 08/03/2026 for an aggregate value of $120,580.62, with the shares traded on NASDAQ.